WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 461866
Description: Oxagrelate is a specific inhibitor of cyclic AMP phosphodiesterase, produced in vitro a concentration-dependent inhibition of platelet aggregation induced by collagen and ADP in human platelets.
MedKoo Cat#: 461866
Chemical Formula: C14H16N2O4
Exact Mass: 276.111
Molecular Weight: 276.29
Elemental Analysis: C, 60.86; H, 5.84; N, 10.14; O, 23.16
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Oxagrelate; EG 626; EG-626; EG626; Oxagrelato; Oxagrelatum; Phthalazinol; SC 32840; SC-32840; SC32840;
IUPAC/Chemical Name: ethyl 1-(hydroxymethyl)-5,7-dimethyl-4-oxo-3,4-dihydrophthalazine-6-carboxylate
InChi Key: DUQOOLBWGUKRAJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H16N2O4/c1-4-20-14(19)11-7(2)5-9-10(6-17)15-16-13(18)12(9)8(11)3/h5,17H,4,6H2,1-3H3,(H,16,18)
SMILES Code: O=C(C1=C(C)C2=C(C(CO)=NNC2=O)C=C1C)OCC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 276.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Azuma H, Takashima Y, Ishikawa M, Yamakado T. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro. Jpn J Pharmacol. 1984 Feb;34(2):159-70. PubMed PMID: 6205194.
2: Agarwal KC, Russo FX, Parks RE Jr. Inhibition of human and rat platelet aggregation by extracts of Mo-er (Auricularia auricula). Thromb Haemost. 1982 Oct 29;48(2):162-5. PubMed PMID: 6983740.
3: Panton RW, Agarwal KC, Robison BS, Parks RE Jr. Murine tumor-induced platelet aggregation and coagulation: mechanisms, inhibitors, and species differences. Thromb Res. 1987 Apr 1;46(1):65-76. PubMed PMID: 3590114.
4: Agarwal KC, Buckley RS, Parks RE Jr. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences. Thromb Res. 1987 Jul 15;47(2):191-200. PubMed PMID: 2821650.